ReviewFrontiers in medicine2022
Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Xanthomatous Reactions in Cutaneous Lupus Erythematosus-More Than an Incidental Finding?Journal of cutaneous pathology · 2026Article
- Secondary Syphilis Masquerading as Systemic Lupus Erythematosus: A Clinicopathologic Diagnostic Challenge.Cureus · 2026Article
- Integrative agent-based modeling of cutaneous lupus: single-cell benchmarking and in silico evaluation of B-cell therapies.Briefings in bioinformatics · 2026Article
- Upregulated GLUT1 expression correlates with type I interferon activity and disease severity in cutaneous lupus erythematosus.Journal of translational autoimmunity · 2026Article
- Dermatological Indicators of Systemic Autoimmune Disease: Clinical Links to Ocular Involvement.Dermatology practical & conceptual · 2026Review
- Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding.Frontiers in immunology · 2026Review
- Hair follicle immune privilege in autoimmune and immune-mediated alopecias: paths toward reestablishing immune tolerance.Frontiers in medicine · 2026Review
- A Rare Case of Coexistence: Discoid Lupus Erythematosus and Sturge-Weber Syndrome.Clinical case reports · 2025Article
- Cutaneous lupus erythematosus - from pathogenesis to targeted therapy.Nature reviews. Rheumatology · 2025Review
- Cutaneous Lupus Features Specialized Stromal Niches and Altered Retroelement Expression.The Journal of investigative dermatology · 2025Article
- An Overview of the Pathogenesis of Cutaneous Lupus Erythematosus.Journal of clinical medicine · 2025Review
- Article
- Anifrolumab has a direct immunoregulatory effect on inflamed keratinocytes: implications for the treatment of lupus erythematosus skin lesions.Frontiers in immunology · 2025Article
- Psoriasis and Lupus Erythematosus-Similarities and Differences between Two Autoimmune Diseases.Journal of clinical medicine · 2024Review
- The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review.Journal of clinical medicine · 2024Review
- The differential panorama of clinical features of lupus erythematosus patients with different onset ages: a cross-sectional multicenter study from China.Clinical rheumatology · 2023Article
- Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.American journal of clinical dermatology · 2023Review
- Aberrant inflammasome activation as a driving force of human autoimmune skin disease.Frontiers in immunology · 2023Review
- Characterization of B cells in lupus erythematosus skin biopsies in the context of different immune cell infiltration patterns.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous lupus erythematosus (CLE) is an interferon (IFN)-driven autoimmune disease that may be limited to the skin or can be associated with systemic lupus erythematosus (SLE). CLE occurs in several morphologic subtypes ranging from isolated, disc-shaped plaques to disseminated skin lesions. The typical histopathologic pattern of skin lesions is named interface dermatitis and characterized by a lymphocytic infiltrate and necroptotic keratinocytes at the dermo-epidermal junction. Other histopathologic patterns primarily involve the dermis or subcutis, depending on the subtype. One critical mechanism in CLE is the chronic reactivation of innate and adaptive immune pathways. An important step in this process is the recognition of endogenous nucleic acids released from dying cells by various pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and other cytosolic receptors. Crucial cells in CLE pathogenesis comprise plasmacytoid dendritic cells (pDCs) as major producers of type I IFN, T cells exerting cytotoxic effects, and B cells, previously believed to contribute
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.